Use of the BioDis to generate a physiologically relevant IVIVC

Journal of Controlled Release

Volumn 130, Issue 3, 2008, Pages 216-219

  Klein, Sandra ^a   Rudolph, Markus W ^b   Skalsky, Brigitte ^c   Petereit, Hans Ulrich ^c   Dressman, Jennifer B ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MERCK KGAA   (Germany)

^c Prod Integrity Dept of Toxicology   (Germany)

Author keywords

BioDis; Colon targeting; EUDRACOL IVIVC; pH gradient

Indexed keywords

BIODIS; COLON TARGETING; GASTRO-INTESTINAL TRACT; PH-GRADIENT; SITE-SPECIFIC DELIVERY;

NITROGEN COMPOUNDS;

CAFFEINE; DRUG VEHICLE; EUDRACOL; EUDRAGIT; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; COLON; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GASTROINTESTINAL TRACT; HUMAN; HUMAN EXPERIMENT; ILEUM; MALE; NORMAL HUMAN; PH MEASUREMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIMULATION; SUSTAINED DRUG RELEASE;

ADJUVANTS, PHARMACEUTIC; BIOLOGICAL AVAILABILITY; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; COLON; DRUG DELIVERY SYSTEMS; FASTING; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MALE; POLYMETHACRYLIC ACIDS;

EID: 50949086237     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.06.014     Document Type: Article

References (22)

1. Ritschel W.A. Targeting in the gastrointestinal-tract-new approaches. Methods Find. Exp. Clin. Pharmacol. 13 5 (1991) 313-336
2. Leopold C.S. Coated dosage forms for colon-specific drug delivery. Pharm. Sci. Technol. Today 2 5 (1999) 197-204
3. Yang L.B., Chu J.S., and Fix J.A. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int. J. Pharm. 235 1-2 (2002) 1-15
4. Azad Khan A.K., Piris J., and Truelove S.C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2 8044 (1977) 892-895
5. Bondesen S., Schou J.B., Pedersen V., Rafiolsadat Z., Hansen S.H., and Hvidberg E.F. Absorption of 5-aminosalicylic acid from colon and rectum. Br. J. Clin. Pharmacol. 25 2 (1988) 269-272
6. Myers B., Evans D.N., Rhodes J., Evans B.K., Hughes B.R., Lee M.G., Richens A., and Richards D. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 28 2 (1987) 196-200
7. Klein S., Stein J., and Dressman J. Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model. J. Pharm. Pharmacol. 57 6 (2005) 709-719
8. Gupta V.K., Beckert T.E., and Price J.C. A novel pH- and time-based multi-unit potential colonic drug delivery system. I. Development. Int. J. Pharm. 213 1-2 (2001) 83-91
9. Gupta V.K., Beckert T.E., Assmus M.W., and Price J.C. A novel pH- and time-based multi-unit potential colonic drug delivery system. II. Optimization of multiple response variables. Int. J. Pharm. 213 1-2 (2001) 93-102
10. Rudolph M.W., Klein S., Beckert T.E., Petereit H., and Dressman J.B. A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur. J. Pharm. Biopharm. 51 3 (2001) 183-190
11. Rall T.W. Central nervous system stimulants. In: Goodman A., and Gilman (Eds). The Pharmacological Basis of Therapeutics 6 (1980), Macmillan Publishing Co. Inc, New York 592-607
12. Axelrod J., and Reichenthal J. The fate of caffeine in man and a method for its estimation in biological material. J. Pharmacol. Exp. Ther. 107 4 (1953) 519-523
13. Coupe A.J., Davis S.S., and Wilding I.R. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm. Res. 8 3 (1991) 360-364
14. Davis S.S., Hardy J.G., and Fara J.W. Transit of pharmaceutical dosage forms through the small intestine. Gut 27 8 (1986) 886-892
15. Bott C., Rudolph M.W., Schneider A.R., Schirrmacher S., Skalsky B., Petereit H.U., Langguth P., Dressman J.B., and Stein J. In vivo evaluation of a novel pH- and time-based multiunit colonic drug delivery system. Aliment. Pharmacol. Ther. 20 3 (2004) 347-353
16. Newton R., Broughton L.J., Lind M.J., Morrison P.J., Rogers H.J., and Bradbrook I.D. Plasma and salivary pharmacokinetics of caffeine in man. Eur. J. Clin. Pharmacol. 21 1 (1981) 45-52
17. Bonati M., Latini R., Galletti F., Young J.F., Tognoni G., and Garattini S. Caffeine disposition after oral doses. Clin. Pharmacol. Ther. 32 1 (1982) 98-106
18. Blanchard J., and Sawers S.J. Comparative pharmacokinetics of caffeine in young and elderly men. J. Pharmacokinet. Biopharm. 11 2 (1983) 109-126
19. Wagner J.G., and Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J. Pharm. Sci. 53 (1964) 1392-1403
20. Levy G., Leonards J.R., and Procknal J.A. Development of in vitro dissolution tests which correlate quantitatively with dissolution rate-limited drug absorption in man. J. Pharm. Sci. 54 12 (1965) 1719-1722
21. Brockmeier D. The correlation of in vitro and in vivo drug dissolution. In: Dressman J.B., and Lennernas H. (Eds). Oral Drug Absorption (2000), Marcel Dekker Inc, New York 281-305
22. Brockmeier D., Dengler H.J., and Voegele D. In vitro-in vivo correlation of dissolution, a time scaling problem? Transformation of in vitro results to the in vivo situation, using theophylline as a practical example. Eur. J. Clin. Pharmacol. 28 3 (1985) 291-300